Novel neurotransmitters and their neuropsychiatric relevance

American Journal of Psychiatry

Volumn 157, Issue 11, 2000, Pages 1738-1751

  Snyder, S H ^a   Ferris, C D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ENDOTHELIUM CELL; EXOCYTOSIS; FLUOROMETRY; MACROPHAGE ACTIVATION; METABOLIC ACTIVATION; NEUROPSYCHIATRY; NEUROTRANSMITTER RELEASE; NONHUMAN; POSTGANGLIONIC NERVE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; REVIEW; SYNAPSE VESICLE; TARGET CELL;

CARBON MONOXIDE; HUMANS; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; SYNAPTIC TRANSMISSION;

EID: 0033765902     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.11.1738     Document Type: Review

References (136)

1. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca
2. Noradrenaline: Fate and control of its biosynthesis
3. Dopamine (3-hydroxytyramine) and brain function
4. Neurotransmitter transporters: Recent progress
5. Histaminergic transmission in the mammalian brain
6. Adenosine as a neuromodulator
7. Neuropeptides in perspective: The last ten years
8. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P
9. Opiate receptor in normal and drug altered brain function
10. Identification of two related pentapeptides from the brain with potent opiate agonist activity
11. Chemical anatomy of the brain
12. Brain peptides: What, where, and why?
13. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
14. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
15. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
16. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates
17. Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate
18. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells
19. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide
20. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain
21. The 42-amino acid insert in the FMN domain of neuronal nitric-oxide synthase exerts control over Ca(2+)/calmodulin-dependent electron transfer
22. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum
23. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices
24. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme
25. Localization of nitric oxide synthase indicating a neural role for nitric oxide
26. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase
27. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase
28. Nitric oxide synthase regulatory sites: Phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites
29. Phosphorylation of nitric oxide synthase by protein kinase A
30. Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase
31. The Akt kinase signals directly to endothelial nitric oxide synthase
32. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
33. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
34. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains
35. PIN: An associated protein inhibitor of neuronal nitric oxide synthase
36. CAPON: A protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95
37. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase
38. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase
39. Endothelial nitric oxide synthase: Molecular cloning and characterization of a distinct constitutive enzyme isoform
40. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line
41. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages
42. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme
43. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter
44. Role of nitric oxide in gastrointestinal and hepatic function and disease
45. Effect of nitric oxide on circular muscle of the canine small intestine
46. Non-adrenergic non-cholinergic relaxation mediated by nitric oxide in the canine ileocolonic junction
47. Targeted disruption of the neuronal nitric oxide synthase gene
48. Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide
49. Carbon monoxide and nitric oxide as coneurotransmitters in the enteric nervous system: Evidence from genomic deletion of biosynthetic enzymes
50. Nitric oxide: A physiologic mediator of penile erection
51. Cyclic GMP phosphodiesterase-5: Target of sildenafil
52. Diabetic gastropathy in mice reflects loss of neuronal nitric oxide synthase that is restored by insulin
53. Genetic evidence for the neuronal nitric oxide synthase gene (NOS1) as a susceptibility locus for infantile pyloric stenosis
54. Nitric oxide synthase activity in infantile hypertrophic pyloric stenosis
55. Diabetic gastropathy: Gastric neuromuscular dysfunction in diabetes mellitus: A review of symptoms, pathophysiology, and treatment
56. Asymptomatic gastric retention in diabetes (gastroparesis diabeticorum)
57. Pyloric dysfunction in diabetics with recurrent nausea and vomiting
58. RNA diversity has profound effects on the translation of neuronal nitric oxide synthase
59. Nitric oxide synthases: Gene structure and regulation
60. Structural organization of the human neuronal nitric oxide synthase gene (NOS1)
61. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase
62. Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone
63. Maternal aggression is reduced in neuronal nitric oxide synthase-deficient mice
64. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase
65. Elimination of aggressive behavior in male mice lacking endothelial nitric oxide synthase
66. Glutamate neurotoxicity and diseases of the nervous system
67. Excitatory amino acid neurotoxicity and neurodegenerative disease
68. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice
69. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse
70. Blockade of nitric oxide formation by N omega-nitro-L-arginine mitigates ischemic brain edema and subsequent cerebral infarction in rats
71. The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia
72. Neuroprotective effects of NG-nitro-L-arginine in focal stroke in the 7-day old rat
73. Effect of nitric oxide synthase inhibition on cerebral blood flow and injury volume during focal ischemia in cats
74. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase
75. Poly(ADP-ribose) polymerase, nitric oxide and cell death
76. Poly(ADP-ribose) in the cellular response to DNA damage
77. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity
78. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
79. Ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase
80. Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia
81. Carbon monoxide: An endogenous modulator of the nitric oxide-cyclic GMP signaling system
82. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury
83. Heme oxygenase-2 is neuroprotective in cerebral ischemia
84. Heme oxygenase-1 prevents cell death by regulating cellular iron
85. Purification and characterization of the major constitutive form of testicular heme oxygenase: The noninducible isoform
86. Characterization of two constitutive forms of rat liver microsomal heme oxygenase: Only one molecular species of the enzyme is inducible
87. Carbon monoxide: A putative neural messenger
88. Direct demonstration of a physiological role for carbon monoxide in olfactory receptor neurons
89. The regulation of heme turnover and carbon monoxide biosynthesis in cultured primary rat olfactory receptor neurons
90. Heme oxygenase 2: Endothelial and neuronal localization and role in endothelium-dependent relaxation
91. Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2
92. Reduction of depolarization-induced glutamate release by heme oxygenase inhibitor: Possible role of carbon monoxide in synaptic transmission
93. Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins
94. Hippocampal long-term potentiation is normal in heme oxygenase-2 mutant mice
95. Bilirubin is an antioxidant of possible physiological importance
96. Antioxidant activity of albumin-bound bilirubin
97. Bilirubin metabolism and kernicterus
98. Influence of bilirubin on the antioxidant capacity of plasma in newborn infants
99. Iron homeostasis, oxidative stress, and DNA damage
100. Reduced stress defense in heme oxygenase 1-deficient cells
101. Heme oxygenase 1 is required for mammalian iron reutilization
102. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2
103. The actions of hydrogen sulfide on dorsal raphe serotonergic neurons in vitro
104. The possible role of hydrogen sulfide as an endogenous neuromodulator
105. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide
106. D-amino acids in animals
107. Free D-aspartate and D-serine in the mammalian brain and periphery
108. Endogenous Dserine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging
109. Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex
110. Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase
111. Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in human temporal cortex: Comparison of normal, Parkinson, and Alzheimer tissues
112. Glycine potentiates the NMDA response in cultured mouse brain neurons
113. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes
114. D-serine, an endogenous synaptic modulator: Localization to astrocytes and glutamate-stimulated release
115. D-serine as a neuromodulator: Regional and developmental localizations in rat brain gila resemble NMDA receptors
116. Purification of serine racemase: Biosynthesis of the neuromodulator D-serine
117. Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission
118. CXCVII. Metabolism of amino acids, III: Deamination of amino acids
119. D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor
120. D-serine is an endogenous ligand for the glycine site of the NMDA receptor: Electrophysiological characterization in cultured hippocampal neurons (abstract)
121. Recent advances in the phencyclidine model of schizophrenia
122. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
123. NMDA receptor hypofunction model of schizophrenia
124. D-serine added to antipsychotics for the treatment of schizophrenia
125. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia (editorial)
126. Presence of D-aspartate in squid axoplasm and in other regions of the cephalopod nervous system
127. Identification of D-aspartic acid in the brain of octopus vulgaris lam
128. Immunohistochemical localization of D-aspartate in the rat pineal gland
129. D-aspartic acid localization during postnatal development of rat adrenal gland
130. The presence of free D-aspartic acid in rodents and man
131. Developmental changes in free D-aspartic acid in the chicken embryo and in the neonatal rat
132. Involvement of D-aspartic acid in the synthesis of testosterone in rat testes
133. Secretion of D-aspartic acid by the rat testis and its role in endocrinology of the testis and spermatogenesis
134. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects
135. Regional decreases of free D-aspartate levels in Alzheimer's disease
136. D-aspartate localizations imply neuronal and neuroendocrine roles